← All trials
NCT04314037
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 6, 2020
- Primary completion
- Sep 25, 2020
- Completion date
- Sep 25, 2020
- First posted
- Mar 18, 2020
- Last posted
- Apr 16, 2020
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Merck KGaALead sponsor
- Merck KGaAStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.